Mexican Tariff (TIGIE) · tariff fraction · HS 3004.90
3004.90.34.00: Other medicines, dosed or for retail sale: Tabletas a base de zolmitriptan.
Other medicines, dosed or for retail sale
✓ Can be used in a customs declaration Data: Mexican Tariff (TIGIE), in force from 14 October 2026 · checked on 24 October 2026
This line has no official text in this language; it is shown in the language of its tariff.
- 3004 Medicamentos (excepto los productos de las partidas 30.02, 30.05 o 30.06) constituidos por productos mezclados o sin mezclar, preparados para usos terapéuticos o profilácticos, dosificados (incluidos los administrados por vía transdérmica) o acondicionados para la venta al por menor.
- 3004.90 Los demás.
- 3004.90.34 Tabletas a base de zolmitriptan.
- 3004.90.34.00 Tabletas a base de zolmitriptan.
What you pay
Importing into Mexico
Customs duty only: import VAT, other taxes and trade defence duties of this country are not covered here, and the duty calculator works only with the EU, Türkiye, US and UK tariffs.
Same subheading in other tariffs
Mexico lines: 3004.90
- 3004.90.01.00Preparaciones a base de cal sodada.
- 3004.90.02.00Medicamentos: los demás, solución isotónica glucosada.
- 3004.90.04.00Medicamentos: los demás, tioleico RV 100.
- 3004.90.05.00Emulsión de aceite de soya al 10% o al 20%, conteniendo 1.2% de lecitina de huevo, con un pH de 5.5 a 9.0, grasa de 9.0% a 11.0% y glicerol de 19.5 mg/ml a 24.5 mg/ml.
- 3004.90.06.00Antineurítico a base de enzima proteolítica inyectable.
- 3004.90.07.00Insaponificable de aceite de germen de maíz.
- 3004.90.08.00Liofilizados a base de 5-etil-5-(1-metilbutil)-2-tiobarbiturato de sodio (Tiopental sódico).
- 3004.90.09.00Solución coloidal de polimerizado de gelatinas desintegradas, conteniendo además cloruros de sodio, de potasio y de calcio.
- 3004.90.11.00Preparación de hidroxialuminato de sodio o de magnesio y sorbitol.
- 3004.90.12.00Medicamentos a base de triyodometano, aminobenzoato de butilo, aceite esencial de menta y eugenol.
- 3004.90.13.00Medicamentos a base de fluoruro de sodio y glicerina.
- 3004.90.14.00Medicamentos en aerosol a base de clorhidrato de tetracaína y amino benzoato de etilo.
- 3004.90.15.00Preparación a base de cloruro de etilo.
- 3004.90.16.00Medicamentos a base de 1-(4-hidroxi-3-hidroximetilfenil)-2-(terbutilamino)etanol, en envase aerosol.
- 3004.90.17.00Mezcla de glucósidos de adonis, convallaria, oleander y scila.
- 3004.90.18.00Medicamentos en tabletas a base de azatioprina o de clorambucil o de melfalan o de busulfan o de 6-mercaptopurina.
- 3004.90.19.00Soluciones inyectables a base de besilato de atracurio o de acyclovir.
- 3004.90.20.00Medicamentos a base de mesilato de imatinib.
- 3004.90.21.00Trinitrato de 1,2,3 propanotriol (nitroglicerina) absorbido en lactosa.
- 3004.90.22.00Medicamentos que contengan azidotimidina (Zidovudina).
- 3004.90.23.00Solución inyectable a base de aprotinina.
- 3004.90.24.00Solución inyectable a base de nimodipina.
- 3004.90.25.00Solución inyectable a base de ciprofloxacina al 0.2%.
- 3004.90.26.00Grageas de liberación prolongada o tabletas de liberación instantánea, ambas a base de nisoldipina.
- 3004.90.27.00A base de saquinavir.
- 3004.90.28.00Tabletas a base de anastrazol.
- 3004.90.29.00Tabletas a base de bicalutamida.
- 3004.90.30.00Tabletas a base de quetiapina.
- 3004.90.31.00Anestésico a base de desflurano.
- 3004.90.32.00Tabletas a base de zafirlukast.
- 3004.90.34.00Tabletas a base de zolmitriptan.
- 3004.90.35.00A base de sulfato de indinavir, o de amprenavir.
- 3004.90.36.00A base de finasteride.
- 3004.90.37.00Tabletas de liberación prolongada, a base de nifedipina.
- 3004.90.38.00A base de octacosanol.
- 3004.90.39.00Medicamentos a base de minerales, en cápsulas de gelatina blanda, aún cuando se presenten en sobres tropicalizados.
- 3004.90.40.00A base de orlistat.
- 3004.90.41.00A base de zalcitabina, en comprimidos.
- 3004.90.43.00Soluciones oftálmicas a base de: norfloxacina; clorhidrato de dorzolamida; o de maleato de timolol con gelán.
- 3004.90.44.00A base de famotidina, en tabletas u obleas liofilizadas.
- 3004.90.45.00A base de montelukast sódico o de benzoato de rizatriptan, en tabletas.
- 3004.90.46.00A base de etofenamato, en solución inyectable.
- 3004.90.47.00Anestésico a base de 2,6-bis-(1-metiletil)-fenol (Propofol), emulsión inyectable estéril.
- 3004.90.48.00Medicamentos a base de cerivastatina, o a base de moxifloxacino.
- 3004.90.49.00Medicamentos a base de: mesilato de nelfinavir; de ganciclovir o de sal sódica de ganciclovir.
- 3004.90.50.00Medicamentos a base de: succinato de metoprolol incluso con hidroclorotiazida; de formoterol; de candesartan cilexetilo incluso con hidroclorotiazida; de omeprazol, sus derivados o sales, o su isómero.
- 3004.90.52.00A base de isotretinoina, cápsulas.
- 3004.90.99.01Preparaciones a base de proteínas hidrolizadas.
- 3004.90.99.02Medicamentos: los demás, medicamentos homeopáticos.
- 3004.90.99.99Medicamentos: los demás.
Binding rulings for similar goods
Decisions of U.S. Customs and Border Protection (CROSS) and HMRC (Advance Tariff Rulings) on goods classified here. A ruling binds only its holder, but shows how the authorities classify similar goods. The descriptions are the authorities’ own, in English.
- N364941 U.S. CBP
The tariff classification of Linezolid Tablets in dosage form, from India
- N364942 U.S. CBP
The tariff classification of Diltiazem Hydrochloride Extended-Release Capsules in dosage form, from India
- N364416 U.S. CBP
The tariff classification of Ranolazine Extended-Release Tablets in dosage form, from India
- N364415 U.S. CBP
The tariff classification of Bupropion Hydrochloride Extended-Release Tablets in dosage form, from India
- 600015874 HMRC
A sterile physiological saline solution Used as an extraocular and intraocular irrigation solution in eye surgery Presented in a plastic bottle with a capacity of 15 ml, and in glass bottles or flexible plastic bags with a capacity of 250 or 500 ml
- 600016281 HMRC
A sterile inhalation saline solution intended to mobilise secretions in the respiratory tract caused by respiratory diseases. The solution contains 3% sodium chloride and is free from preservatives. It is packaged in 20 × 4 ml ampoules for use with a jet, membrane, or ultrasonic nebuliser.
- 600015890 HMRC
Formoline L112 tablets to support weight management and reduction of dietary fat absorption and lowering of LDL cholesterol active component is polyglucosamine, also contain excipients used in tablet manufacture, including binders, fillers and coating materials packed in boxes of 64 tablets, with…
- 600013517 HMRC
radiopharmaceutical containing the radioactive isotope Lutetium-177 single patient dose, administered intravenously, via the vial Physical form: liquid Use: in clinical trials for assessment of its performance as a therapeutic medicine in humans Packaging :a vial held within shielded container to…
562 rulings in total for this code
Legal notes
Notes
1. This chapter does not cover:
(a) foods or beverages (such as dietetic, diabetic or fortified foods, food supplements, tonic beverages and mineral waters), other than nutritional preparations for intravenous administration (Section IV);
(b) products, such as tablets, chewing gum or patches (transdermal systems), containing nicotine and intended to assist tobacco use cessation (heading 2404);
(c) plasters specially calcined or finely ground for use in dentistry (heading 2520);
(d) aqueous distillates or aqueous solutions of essential oils, suitable for medicinal uses (heading 3301);
(e) preparations of headings 3303 to 3307, even if they have therapeutic or prophylactic properties;
(f) soap or other products of heading 3401 containing added medicaments;
(g) preparations with a basis of plaster for use in dentistry (heading 3407);
(h) blood albumin not prepared for therapeutic or prophylactic uses (heading 3502); or
(ij) diagnostic reagents of heading 3822.
2. For the purposes of heading 3002, the expression ‘immunological products’ applies to peptides and proteins (other than goods of heading 2937) which are directly involved in the regulation of immunological processes, such as monoclonal antibodies (MAB), antibody fragments, antibody conjugates and antibody fragment conjugates, interleukins, interferons (IFN), chemokines and certain tumour-necrosis factors (TNF), growth factors (GF), hematopoietins and colony-stimulating factors (CSF).
3. For the purposes of headings 3003 and 3004 and of note 4(d) to this chapter, the following are to be treated:
(a) as unmixed products:
(1) unmixed products dissolved in water;
(2) all goods of Chapter 28 or 29; and
(3) simple vegetable extracts of heading 1302, merely standardised or dissolved in any solvent;
(b) as products which have been mixed:
(1) colloidal solutions and suspensions (other than colloidal sulphur);
(2) vegetable extracts obtained by the treatment of mixtures of vegetable materials; and
(3) salts and concentrates obtained by evaporating natural mineral waters.
4. Heading 3006 applies only to the following, which are to be classified in that heading and in no other heading of the nomenclature:
(a) sterile surgical catgut, similar sterile suture materials (including sterile absorbable surgical or dental yarns) and sterile tissue adhesives for surgical wound closure;
(b) sterile laminaria and sterile laminaria tents;
(c) sterile absorbable surgical or dental haemostatics; sterile surgical or dental adhesion barriers, whether or not absorbable;
(d) opacifying preparations for X-ray examinations and diagnostic reagents designed to be administered to the patient, being unmixed products put up in measured doses or products consisting of two or more ingredients which have been mixed together for such uses;
(e) placebos and blinded (or double-blinded) clinical trial kits for use in recognised clinical trials, put up in measured doses, even if they might contain active medicaments;
(f) dental cements and other dental fillings; bone reconstruction cements;
(g) first-aid boxes and kits;
(h) chemical contraceptive preparations based on hormones, on other products of heading 2937 or on spermicides;
(ij) gel preparations designed to be used in human or veterinary medicine as a lubricant for parts of the body for surgical operations or physical examinations or as a coupling agent between the body and medical instruments;
(k) waste pharmaceuticals, that is, pharmaceutical products which are unfit for their original intended purpose due to, for example, expiry of shelf life; and
(l) appliances identifiable for ostomy use, that is, colostomy, ileostomy and urostomy pouches cut to shape and their adhesive wafers or faceplates.
Subheading notes
1. For the purposes of subheadings 300213 and 300214, the following are to be treated:
(a) as unmixed products, pure products, whether or not containing impurities;
(b) as products which have been mixed:
(1) the products mentioned in (a) above dissolved in water or in other solvents;
(2) the products mentioned in (a) and (b) (1) above with an added stabiliser necessary for their preservation or transport; and
(3) The products mentioned in (a), (b) (1) and (b) (2) above with any other additive.
2. Subheadings 300360 and 300460 cover medicaments containing artemisinin (INN) for oral ingestion combined with other pharmaceutical active ingredients, or containing any of the following active principles, whether or not combined with other pharmaceutical active ingredients: amodiaquine (INN); artelinic acid or its salts; artenimol (INN); artemotil (INN); artemether (INN); artesunate (INN); chloroquine (INN); dihydroartemisinin (INN); lumefantrine (INN); mefloquine (INN); piperaquine (INN); pyrimethamine (INN) or sulfadoxine (INN).
Additional note
1. Heading 3004 includes herbal medicinal preparations and preparations based on the following active substances: vitamins, minerals, essential amino-acids or fatty acids, in packings for retail sale. These preparations are classified in heading 3004 if they bear on the label, packaging or on the accompanying user directions the following statements of:
(a) the specific diseases, ailments or their symptoms for which the product is to be used;
(b) the concentration of active substance or substances contained therein;
(c) dosage; and
(d) mode of application.
This heading includes homeopathic medicinal preparations when they meet the conditions of (a), (c) and (d) mentioned above.
In the case of preparations based on vitamins, minerals, essential amino-acids or fatty acids, the level of one of these substances per recommended daily dose indicated on the label must be significantly higher than the recommended daily allowance to maintain general health or well-being.
Tariff fraction 3004.90.34.00 is a line of the Mexican Tariff (TIGIE) under HS subheading 3004.90 (medicaments: other).
The import duty (IGI) is free, and quantities are declared in Kg.
For the same subheading, the UK duty is free, the EU duty is free, the Türkiye duty is free, the US duty is free, the Canada duty is free, the Brazil duty is 0%–14%, the Argentina duty is 0%–12.6%, the Peru duty is 6%, the New Zealand duty is free, the Japan duty is free, the Taiwan duty is 0%–20%, the GCC duty is free, the Switzerland duty is free, the Norway duty is free, the North Macedonia duty is 5% and the Nigeria duty is free.
Mexico imported goods of subheading 3004.90 worth US$3.3bn in 2024; the largest supplier was the United States.
Questions and answers
What is the Mexico import duty for tariff fraction 3004.90.34.00?
The import duty (IGI) in the Mexican Tariff (TIGIE) is free; the supplementary unit is Kg. This page shows the rate as published by the national source and, where the source publishes them, preferential rates: choose the country of origin to see them. Trade defence duties and VAT are not covered.
Where does Mexico import these goods from?
For subheading 3004.90 as a whole, the largest supplier in 2024 was the United States (US$870m), followed by Germany.
Typical products
Everyday names, not part of the legal text.